Steve, this is Scott. I will talk regarding the revenue. So just to clarify, we did raise the revenue guidance in total from $55,000,000,000 to $55,500,000,000 a $500,000,000 raise and that included a $300,000,000 raise for SKYRIZI, a $100,000,000 raise for RINVOQ, a $100,000,000 raise for VENCLEXTA, dollars 200,000,000 spread across other products and then a $200,000,000 reduction in the guidance for aesthetics. So we do see very strong momentum in the business, and we did raise our sales guidance from $55,000,000 to $55,500,000,000